Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7

NCT06020755 | Recruiting Phase 2

• 1 other identifier: TA7-GTN-001
• Study Type: interventional
• Target: 17
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to evaluate the efficacy and safety of toripalimab plus actinomycin-D as fist-line treatment in patients with gestational trophoblastic neoplasia with FIGO score 7. The main questions it aims to answer are:

• Whether toripalimab plus actinomycin-D as fist-line treatment can achieve a high complete response rate.
• Whether an equally high cure rate can be achieved by multi-drug chemotherapy as second-line treatment in patients who have failed fist-line treatment with toripalimab plus actinomycin-D. Participants will receive toripalimab plus actinomycin-D. Treatment will be continued until disease progression, unacceptable toxicity, or withdrawal of consent. Treatment will be completed after 4 consolidation cycles.

Conditions

Gestational Trophoblastic Neoplasia

Keywords

Gestational Trophoblastic Neoplasia; International Federation of Gynecology and Obstetrics; Toripalimab; Actinomycin-D; Efficacy; Safety

Outcome Measures

Primary Outcomes (1)

• Complete remission rate

  The proportion of patients achieving complete remission. Complete remission is defined as normal serum β-hCG level measured for 4 consecutive weeks.

  up to one year

Secondary Outcomes (10)

• Objective response rate

  up to one year

• Progression-free survival

  up to one year

• Disease control rate

  up to one year

• Duration of response

  up to one year

• Overall survival

  up to one year

Study Arms (1)

Toripalimab Plus Actinomycin-D

EXPERIMENTAL

Toripalimab 200mg intravenously(IV) every 2 weeks (Q2W) Actinomycin-D 1.25mg/m2，2mg max dos, intravenously(IV) every 2 weeks (Q2W)

Drug: Toripalimab; Drug: Actinomycin-D

Interventions

Toripalimab DRUG

200mg q2w intravenous

Toripalimab Plus Actinomycin-D

Actinomycin-D DRUG

1.25mg/m2，2mg max dose, q2w, intravenous

Toripalimab Plus Actinomycin-D

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Diagnosed as GTN:
• There is a histologic diagnosis of choriocarcinoma or invasive mole. Postmolar GTN: The plateau of β-hCG (±10%) lasts for four measurements over a period of 3 weeks or longer (days 1, 7, 14, 21). There is a rise (\>10%) in β-hCG for three consecutive weekly measurements over at least a period of 2 weeks or more (days 1, 7, 14).
• GTN after nonmolar pregnancy: There is a rise after decease, or a plateau of β-hCG 4 weeks after abortion, ectopic pregnancy, or term delivery. Pregnancy residue or new pregnancy have been ruled out.
• Patients with a FIGO score of 7.
• Signed informed consent.
• No previous immunotherapy, chemotherapy, or radiotherapy.
• Woman aged 18-60 years.
• Expected survival ≥ 6 months.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 7 days before first dose.
• The function of vital organs meets the following requirements:
• hemoglobin ≥90 g/L, absolute neutrophil count ≥1·5×109/L, platelets ≥100×109/L; creatinine ≤1·5 × upper limit of normal (ULN), urea nitrogen ≤2·5×ULN; total bilirubin ≤1.5×ULN, alanine aminotransferase and aspartate aminotransferase ≤2·5×ULN, INR, PT or APTT ≤1.5×ULN, thyroid stimulating hormone ≤ULN (if thyroid stimulating hormone is abnormal, normal T3 and T4 can also be acceptable).

You may not qualify if:

• Histologically confirmed placental-site trophoblastic tumor (PSTT) or epithelioid trophoblastic tumor (ETT).
• Histologically confirmed primary choriocarcinoma.
• Other malignancies in the past 3 years.
• Prior systemic anti-cancer treatment, including chemotherapy and radiotherapy.
• Live vaccines injected within 30 days before the first dose of study drug;
• Systemic immune stimulant agent (such as a bacterial or viral vaccine, colony-stimulating factors, interferon, interleukin, and combined vaccine) was used 6 weeks before administration or within the 5 half-lives of the drug, whichever is shorter.
• Previous treatment with immunotherapy drugs (including antibodies targeting PD-1, PD-L1, PD-L2, cytotoxic T-lymphocyte-associated protein 4, T-cell receptor, chimeric antigen receptor T-cell therapy, and other immunotherapy).
• Known hypersensitivity or allergy to actinomycin-D, toripalimab or any of their excipients.
• Any active autoimmune disease requiring systemic treatment during the past 2 years.
• History or current status of non-infectious pneumonia requiring steroid treatment.
• Receiving steroid hormones (prednisone dose \> 10mg/ day) or other immunosuppressants within 14 days before enrollment, excluding those on hormone replacement therapy.
• Active infection that requires systemic treatment.
• Human immunodeficiency virus infection or known acquired immunodeficiency syndrome, active hepatitis B, hepatitis C.
• History of psychotropic drug abuse and are unable to withdraw the psychotropic drug, or have mental disorders.
• Grade II or higher myocardial ischemia, myocardial infarction or poorly controlled arrhythmia (females with QTc interval ≥470 ms); grade III to IV cardiac insufficiency according to New York Heart Association (NYHA) criteria, or cardiac color Doppler ultrasound evidence of left ventricular ejection fraction \<50%; myocardial infarction, NYHA grade II or above heart failure, uncontrolled angina, uncontrolled severe ventricular arrhythmia, clinically significant pericardial disease, or electrocardiogram suggesting acute ischemia or abnormal active conduction system occurring within 6 months before enrolment.

Sponsors & Collaborators

• Peking Union Medical College Hospital: lead
• Obstetrics & Gynecology Hospital of Fudan University: collaborator
• Shengjing Hospital: collaborator
• Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University: collaborator
• Henan Cancer Hospital: collaborator
• Gansu Provincial Maternal and Child Health Care Hospital: collaborator
• Dalian Maternity and Child Care Hospital: collaborator
• The First Affiliated Hospital of Xiamen University: collaborator
• Sichuan Cancer Hospital and Research Institute: collaborator
• Shanghai Junshi Bioscience Co., Ltd.: collaborator

Study Sites (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

RECRUITING

MeSH Terms

Conditions

Gestational Trophoblastic Disease

Interventions

toripalimab; Dactinomycin

Condition Hierarchy (Ancestors)

Trophoblastic Neoplasms; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Pregnancy Complications, Neoplastic; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases

Intervention Hierarchy (Ancestors)

Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Peptides, Cyclic; Macrocyclic Compounds; Polycyclic Compounds; Peptides; Amino Acids, Peptides, and Proteins

Central Study Contacts

Yang Xiang

CONTACT

+861069156068; xiangy@pumch.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: August 25, 2023
• First Posted: September 1, 2023
• Study Start: December 1, 2024
• Primary Completion: August 1, 2025
• Study Completion: August 1, 2025
• Last Updated: December 31, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)